Chronic Myeloid Leukemia Clinical Trial
Official title:
A Multicenter, Open Label Cohort Phase 1 Dose Finding Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 Mesylate for Oral Administration in Adult Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML), Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
Verified date | February 2020 |
Source | Fusion Pharma LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A multicenter, open label cohort Phase 1 dose finding study to evaluate tolerability, safety, pharmacokinetics and preliminary efficacy of PF-114 for oral administration in adult patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML), which is resistant to the 2-nd generation Bcr-Abl inhibitors or has T315I mutation in the BCR-ABL gene.
Status | Active, not recruiting |
Enrollment | 65 |
Est. completion date | May 2020 |
Est. primary completion date | June 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Patients must meet all of the following criteria in order to be eligible for participation in the study: 1. Able to give written informed consent; 2. Male or female patient = 18 years old; 3. Confirmed diagnosis of CML in chronic or accelerated phase according to European LeukemiaNet guideline as of 2013; 4. Available information regarding resistance to the therapy with least one 2-nd generation Bcr-Abl inhibitor (dasatinib or nilotinib or bosutinib), or intolerance of approved Bcr-Abl inhibitors, or presence of T315I mutation irrespective of treatment history; 5. In case of previous history of blast crisis phase of CML at least 6 months are required to pass after the end of blast crisis phase before the first dose of PF-114; 6. ECOG performance status = 2 (see Appendix 2); 7. Adequate renal function defined as serum creatinine = 1.5 times upper limit of normal (ULN); 8. Adequate hepatic function defied as: - serum bilirubin = 1.5 X ULN unless a patient is diagnosed with Gilbert's syndrome; - serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 X ULN; - alkaline phosphatase = 2.5 X ULN; - INR = 1.5 X ULN; 9. Adequate cardiac function defined as LVEF > 40 % by echocardiogram; 10. QTcF < 470 ms; 11. Patient has recovered (to Grade 1 or less according to NCI CTCAE V 4.0) from toxicities (excluding alopecia) associated with any prior treatments; 12. Female patients of childbearing potential and male patients who have female partners of childbearing potential must agree with abstinence from sexual relations or use effective methods of contraception throughout participation in the study; 13. Ability to comply with study procedures in the Investigator's opinion. Exclusion Criteria: Patients must not meet any of the following criteria in order to be eligible for participation in the study: 1. Use of the following previous therapy: 1. chemotherapy = 21 days (except hydroxyurea for which washout is not required) prior to the first dose of PF-114 mesylate; ?r nitrosoureas ?r mitomycin ? = 42 days prior to the first dose of PF-114 mesylate; 2. approved tyrosine kinase inhibitors or investigational agents = 4 days prior to the first dose of PF-114; 3. radiotherapy = 28 days prior to the first dose of PF-114 ; 4. autologous ?r allogeneic stem ??ll transplant < 90 days prior to enrollment; 2. Significant uncontrolled cardiac disease; 3. Sustained uncontrolled hypertension = Grade 2 (according to NCI CTC AE v4); 4. Patient is taking medicinal products known to prolong the QT interval on the electrocardiogram, unless they are absolutely necessary in the opinion of the investigator; 5. Evidence of on-going graft versus host disease (GVHD), or GVHD requiring immunosuppressive therapy. Patients should be off immunosuppressive therapy for prophylaxis and/or treatment for at least 14 days prior to the first dose of PF-114; 6. Major surgery within 35 days prior to enrollment; 7. Uncontrolled intercurrent illness including, but not limited to the following: active systemic infection, uncontrolled seizure disorder, psychiatric or social circumstances that would limit compliance with study requirements or misrepresent results of the study; 8. Patient is unable to swallow study drug or has gastro-intestinal disorders that could negatively affect oral absorption of PF-114 ; 9. Any malignancy other than CML within the past 3 years (except for non-melanoma skin cancer or cervical cancer in situ). 10. Pregnancy or breast feeding. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Federal Haematological Scientific Center | Moscow | |
Russian Federation | Moscow City Centre of Hematology based on City Hospital named by S.Botkin | Moscow | |
Russian Federation | Federal Almazov North-West Medical Research Centre | St. Petersburg |
Lead Sponsor | Collaborator |
---|---|
Fusion Pharma LLC | Data Matrix Solutions, OCT Rus, LLC, Skolkovo Innovation Center |
Russian Federation,
Mian AA, Rafiei A, Haberbosch I, Zeifman A, Titov I, Stroylov V, Metodieva A, Stroganov O, Novikov F, Brill B, Chilov G, Hoelzer D, Ottmann OG, Ruthardt M. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelph — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Pharmacodynamic response criterion to PF-114 (change in the level of pCrkL in PBL during therapy compared to baseline level) | To assess pharmacodynamic response to PF-114 mesylate in patients who are not in complete hematologic response upon enrollment into the study by measuring the difference of pCrkL levels in peripheral blood leukocytes (PBL) during therapy compared to baseline | 20 months | |
Other | The number of patients who satisfy the pharmacodynamic response criterion depending on the mutation status of BCR-ABL | 20 months | ||
Other | The number of patients who satisfy the hematologic response depending on the mutation status of BCR-ABL | 20 months | ||
Other | The number of patients who satisfy the cytogenetic response depending on the mutation status of BCR-ABL | 20 months | ||
Other | The number of patients who satisfy the molecular response depending on the mutation status of BCR-ABL | 20 months | ||
Primary | DLTs during the first cycle of therapy | To study the dose-limiting toxicities (DLTs) of PF-114 mesylate in the target patient population during the 1-st cycle of treatment | 1-st Cycle of Therapy - 28 days | |
Primary | MTD | Primary Objectives: To determine the maximum tolerated dose (MTD) of PF-114 in the target patient population. |
1-st Cycle of Therapy - 28 days | |
Secondary | The incidence of AEs | To assess the safety and tolerability of PF-114 in the target patient population | through study completion, an average of 1 year | |
Secondary | Cmax for oral PF-114 in the target patient population | 31 days | ||
Secondary | Tmax for oral PF-114 in the target patient population | 31 days | ||
Secondary | AUC0-t for oral PF-114 in the target patient population | 31 days | ||
Secondary | AUC0-8 for oral PF-114 in the target patient population | 31 days | ||
Secondary | T1/2 for oral PF-114 in the target patient population | 31 days | ||
Secondary | CL/F for oral PF-114 in the target patient population | 31 days | ||
Secondary | Vd/F for single and multiple dosing for oral PF-114 in the target patient population | 31 days | ||
Secondary | Ctrough for multiple dosing for oral PF-114 in the target patient population | 31 days | ||
Secondary | Hematological response to the treatment based on European LeukemiaNet criteria, 2013. | Hematological response is evaluated on Day 1 of each therapy cycle Full hematologic response: Leukocytes < 10 ? 109 /L Basophils < 5 % Thrombocytes < 450 ? 109 /L No myelocytes, promyelocyts, myeloblasts in the differential Absence of splenomegaly - spleen non palpable |
through study completion, an average of 1 year | |
Secondary | Molecular response - the level of BCR-ABL transcripts in the peripheral blood, determined by the method of quantitative polymerase chain reaction (qPCR) using the international scale. | Molecular response is evaluated on Day 1 of Cycles 2, 4, 7, 10. For cycles > 12, the molecular response will be evaluated once in 3 months, where the procedure is carried out for the first time during Cycle 13. | through study completion, an average of 1 year | |
Secondary | Cytogenetic response evaluated using the chromosome banding method (in situ (FISH) fluorescence hybridization is allowed only if the chromosome banding method cannot provide enough information). | Cytogenetic response is evaluated on Day 1, Cycles 4, 7, 13. Then if the level of BCR-ABL transcripts exceeds the level of 0.1% using the qPCR method using the international scale, cytogenetic response is evaluated no earlier than in 3 months after the previous cytogenetic analysis. After the complete cytogenetic response has been reached (CCyR), cytogenetic analysis will be carried out every 12 months. | through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Completed |
NCT02057185 -
Occupational Status and Hematological Disease
|
||
Recruiting |
NCT03326310 -
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
|
Phase 1 | |
Recruiting |
NCT04621851 -
Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation
|
||
Completed |
NCT01207440 -
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
Not yet recruiting |
NCT06409936 -
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
|
Phase 2 | |
Active, not recruiting |
NCT02917720 -
2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients
|
Phase 2 | |
Not yet recruiting |
NCT02883036 -
Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia
|
N/A | |
Withdrawn |
NCT01188889 -
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
|
Phase 1/Phase 2 | |
Completed |
NCT01795716 -
Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
|
Phase 1 | |
Completed |
NCT00988013 -
Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
|
N/A | |
Approved for marketing |
NCT00905593 -
Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
|
Phase 3 | |
Terminated |
NCT00573378 -
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
|
Phase 2 | |
Completed |
NCT00469014 -
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
|
Phase 2 | |
Terminated |
NCT00522990 -
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
|
Phase 1/Phase 2 | |
Completed |
NCT00257647 -
Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML)
|
N/A | |
Unknown status |
NCT00598624 -
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)
|
Phase 2 | |
Completed |
NCT00219739 -
STI571 ProspectIve RandomIzed Trial: SPIRIT
|
Phase 3 | |
Completed |
NCT06148493 -
Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database
|
||
Completed |
NCT00375219 -
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
|
Phase 2 |